News & Events
Showcasing the latest news stories and event headlines from the world of Neurology

Multiple sclerosis management in the elderly

5692 3201 Samyuktha Pillai, PhD

The life expectancy in multiple sclerosis (MS) continues to increase and is now comparable to that of the general population.1 This increase comes with the…

read more

Preliminary results from stem cell transplantation as an MS therapy in Switzerland

5692 3201 Samyuktha Pillai, PhD

Autologous hematopoietic stem cell transplantation (aHSCT) has been used in the treatment of multiple sclerosis (MS) since 1995 and was approved in Switzerland in June…

read more

MS 2022: Upcoming therapies, and their pros and cons

5692 3201 Samyuktha Pillai, PhD

The repertoire of available multiple sclerosis (MS) disease modifying therapies (DMTs) is constantly growing. In recent years, there have been several new DMTs that have…

read more

Key pharmacological recommendations for hospitalised COVID‑19 patients: A German national treatment guidance

1500 1000 Noreen Hussain, PharmD

During the current coronavirus 2019 disease (COVID-19) pandemic, research is being developed and disseminated at an accelerated pace.1 The constant influx of data can be…

read more

Cognitive deficits related to COVID-19: The challenge of measuring association

2560 1707 Akshar Patel

There has been increasing worry about possible cognitive consequences related to COVID-19 and recent case studies have revealed neurological problems in severely affected patients.1 Growing…

read more

What are the implications for the third COVID-19 vaccine on CD-20-depleted people with MS – Oliver Findling reports

1500 1001 Shawn Haigh

In a guest post on “The MS Blog,” Dr Oliver Findling summarised a recent study on which he was the principal investigator: Humoral Immune Response…

read more

Speaking to Prof. Mary Reilly – “Complex cases are part of the attraction“

1300 1329 Anna Stelling, PhD

Prof. Mary Reilly is a consultant neurologist at the National Hospital for Neurology and Neurosurgery and a professor of clinical neurology, heading the division of…

read more

Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

960 640 Brainwork

The CENTAUR phase 2, randomised, placebo-controlled trial included patients with amyotrophic lateral sclerosis (ALS) who received a fixed dose formulation of sodium phenylbutyrate-taurursodiol (PB-TURSO). The…

read more

Getting the complete clinical picture: A closer look at smouldering MS

6641 3734 Howard Donohue, PhD

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS,…

read more

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

6641 3734 Howard Donohue, PhD

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus,…

read more

Aquaporin-4-positive neuromyelitis optica spectrum disorder: A favourable long-term benefit-risk profile of eculizumab treatment

6641 3734 Howard Donohue, PhD

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease that typically affects the optic nerves and spinal cord.1,2 At least two-thirds of cases are…

read more
Brainwork is supported by unrestricted grants from: